DMRA (Damora Therapeutics, Inc.) PDUFA Date | FDA Catalyst & Approval Status

Jul 17, 2026

Damora Announces Redomestication from Delaware to Cayman Islands

Damora Therapeutics has completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026. This transition involved the automatic conversion of shares without altering the company's business structure or obligations. The ordinary shares will continue trading on Nasdaq under the symbol DMRA, with a new CUSIP effective July 20, 2026.

May 13, 2026

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Damora Therapeutics reported strong first-quarter results for 2026, highlighting significant progress in its mutCALR-targeted therapy pipeline. The company is on track to submit regulatory filings for its lead programs, DMR-001 and DMR-002, in mid-2026. Despite a net loss of $27.8 million, Damora maintains a robust cash position, expected to fund operations into 2029.

May 1, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics has announced the granting of equity awards to two new non-executive employees as part of their inducement strategy under Nasdaq Listing Rule 5635(c)(4). The grants include non-qualified stock options for a total of 57,500 shares, with a defined vesting schedule. This move aims to enhance the company's capabilities in developing treatments for blood disorders.

Mar 23, 2026

▲ +27.1%on this news· ran to +41% by day 3

Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors -- Ms. Jarrett brings nearly three decades of executive leader

Damora Therapeutics has appointed Jennifer Jarrett as President and CEO, effective March 30, 2026. With nearly three decades of experience in biotech, she is expected to drive the company’s efforts in developing therapies for blood disorders, specifically mutant calreticulin-driven myeloproliferative neoplasm. Alongside her, two new board members, Cameron Turtle and Mike Landsittel, bring significant industry expertise, strengthening Damora's leadership as it seeks to advance its pipeline of potential therapies.

Mar 10, 2026

Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders -- Company will trade on Nasdaq under trading symbol DMRA effective

Galecto, Inc. has renamed itself Damora Therapeutics and will trade under the symbol DMRA starting March 10, 2026. The rebranding follows the acquisition of Damora and recent funding that strengthens its financial position. Damora aims to advance its therapy pipeline targeting mutCALR-driven blood disorders, with plans to submit IND applications for DMR-001 in mid-2026. The company emphasizes its focus on developing disease-modifying treatments for conditions currently lacking targeted therapies.

Jan 12, 2026

Company Logo Disclaimers The information contained in this presentation has been prepared by Galecto Inc. and its affiliates (“Galecto” or the “Company”) and contains information pertaining to

Galecto Inc. has acquired Damora Therapeutics, boosting its portfolio of therapies targeting mutant CALR-driven myeloproliferative neoplasms. The lead program, which is a subcutaneous anti-mutCALR monoclonal antibody, shows promise based on demonstrated clinical proof-of-concept. This acquisition positions Galecto to potentially establish a new standard of care in treating essential thrombocythemia and myelofibrosis. Galecto aims to transform treatment for patients with these conditions through innovative therapeutics.

Nov 10, 2025

Galecto Announces Acquisition of Damora Therapeutics Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve out

Galecto, Inc. has completed the acquisition of Damora Therapeutics, enhancing its portfolio of therapies targeting mutant calreticulin-driven Myeloproliferative Neoplasms (MPNs). The acquisition is supported by an oversubscribed private investment of approximately $285 million, which will enable Galecto to advance clinical programs, including the lead candidate DMR-001 expected to enter Phase 1 trials with proof-of-concept data anticipated in 2027. This strategic merger aims to improve treatment outcomes for patients suffering from MPNs, including Essential Thrombocythemia and Myelofibrosis.

Oct 15, 2024

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler BOSTON

Galecto, Inc. announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler, a board-certified dermatologist and psychiatrist, brings significant industry experience and a successful record in supporting companies through critical growth phases. She is expected to provide strategic insights for the development of Galecto’s oncology pipeline. With a background in health management and clinical practice, her addition is viewed as a positive step for the company.

Oct 7, 2024

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On

On October 7, 2024, DMRA completed the Closing of an Asset Purchase, with unaudited pro forma financial statements provided to illustrate potential adjustments. These financials suggest how the transaction might have impacted historical figures had it occurred earlier. However, the information is for informational purposes only and does not guarantee future results. The company also executed a reverse stock split at a ratio of 1-for-25, impacting the historical data used in these pro forma statements.

Oct 23, 2023

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211

Galecto, Inc. presented updated clinical data at the ESMO Congress 2023 related to its Phase 1b/2a GALLANT-1 trial of GB1211 combined with atezolizumab for treating advanced non-small cell lung cancer. The trial showed a 60% partial response rate in five patients, suggesting the combination may enhance treatment efficacy compared to atezolizumab alone. However, severe reactions at higher doses led to a dose reduction, and the company has decided not to proceed with Part B of the GALLANT-1 trial, opting to refocus on severe liver diseases. Galecto plans to initiate a new Phase 2 trial in early 2024 and seek external partnerships for oncology activities.

Sep 26, 2023

Galecto Announces Plans to Explore Strategic Alternatives Boston, MA

Galecto, Inc. has announced plans to explore strategic alternatives aimed at maximizing shareholder value, following a review of its business status. This process may involve various actions such as acquisitions, mergers, or asset divestitures, though no specific outcomes are guaranteed. Notably, the company plans to reduce its workforce by about 70% as part of a restructuring plan. As of mid-2023, Galecto reported a cash balance of $52.1 million, indicating some financial stability while it navigates this process.

Aug 15, 2023

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis Announces next steps for clinical development plan in severe liver diseases Boston, MA

Galecto, Inc. announced topline results from its Phase 2b GALACTIC-1 trial for GB0139 in treating idiopathic pulmonary fibrosis, which did not meet its primary efficacy endpoint. Consequently, Galecto will cease development of GB0139 and shift focus to severe liver diseases with their oral candidate, GB1211. The company plans to initiate a Phase 2a trial for GB1211 targeting decompensated cirrhosis early in 2024, pending financing. Despite the setback with GB0139, past trials for GB1211 suggest positive clinical outcomes.

Jan 6, 2023

Forward-looking statements This presentation contains forward-looking statements about Galecto, Inc.'s (“Galecto” or the “Company”) strategy, future plans, operations and prospects, including,

Galecto, Inc. recently provided a presentation on its forward-looking plans and the status of its drug development pipeline, which includes first-in-class small molecule antifibrotic and anticancer agents. The company reported a strong cash balance that supports its ongoing Phase 2 clinical trials. However, it acknowledged the significant risks and uncertainties surrounding drug development and regulatory approvals that could impact timelines and outcomes. Among the candidates, GB0139 is highlighted for its potential in treating idiopathic pulmonary fibrosis (IPF) with a unique inhaled delivery method.

Oct 31, 2022

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting 2022 • Late-breaking oral and poster presentations include clinical and

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting 2022 -Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trial -Galecto to

Sep 29, 2022

DMRAConferences/Events

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target Company to host a live conference call and webcast today

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target Company to host a live conference call and webcast today, September 29, 2022, at 8:00 a.m. ET Boston, MA, September 29, 2022 - Galecto, Inc. (NAS

Jan 27, 2022

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care Results Support Favorable Safety and Tolerability Profile and Target

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lun

Jan 5, 2022

DMRAConferences/Events

Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation

First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2022 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fac

Mar 15, 2021

Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications Galecto expects to c

Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg

Jan 8, 2021

Galecto Appoints Anne Prener to its Board of Directors Boston

Galecto Appoints Anne Prener to its Board of Directors Boston, Jan. 8, 2021 (GLOBE NEWSWIRE) - Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne

Jan 5, 2021

DMRAConferences/Events

First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2021 Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All state

First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2021 Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained

Nov 23, 2020